270,000 Shares in Indivior PLC (NASDAQ:INDV) Purchased by Stonepine Capital Management LLC

Stonepine Capital Management LLC bought a new position in Indivior PLC (NASDAQ:INDV) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 270,000 shares of the company’s stock, valued at approximately $2,632,000. Indivior makes up 1.7% of Stonepine Capital Management LLC’s holdings, making the stock its 21st largest position. Stonepine Capital Management LLC owned 0.20% of Indivior at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. Cubist Systematic Strategies LLC increased its stake in Indivior by 32.0% during the second quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company’s stock worth $407,000 after acquiring an additional 6,121 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Indivior during the second quarter valued at approximately $188,000. VELA Investment Management LLC bought a new position in shares of Indivior during the second quarter valued at approximately $235,000. XTX Topco Ltd bought a new position in shares of Indivior during the second quarter valued at approximately $249,000. Finally, Janus Henderson Group PLC grew its stake in shares of Indivior by 14.2% during the first quarter. Janus Henderson Group PLC now owns 440,121 shares of the company’s stock valued at $9,424,000 after buying an additional 54,750 shares during the last quarter. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Indivior Trading Down 1.3 %

NASDAQ:INDV traded down $0.15 during midday trading on Wednesday, hitting $11.03. The stock had a trading volume of 131,108 shares, compared to its average volume of 525,204. Indivior PLC has a one year low of $7.33 and a one year high of $23.22. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -279.43 and a beta of 0.70. The stock has a 50-day moving average of $9.53 and a 200 day moving average of $12.42. The company has a quick ratio of 0.65, a current ratio of 0.83 and a debt-to-equity ratio of 23.50.

Indivior (NASDAQ:INDV) last posted its earnings results on Thursday, October 24th. The company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.15. The company had revenue of $307.00 million during the quarter, compared to analyst estimates of $302.25 million. Indivior had a negative return on equity of 351.08% and a negative net margin of 0.17%. As a group, sell-side analysts forecast that Indivior PLC will post 1.66 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on INDV. Piper Sandler reaffirmed an “overweight” rating and set a $16.00 target price (up previously from $15.00) on shares of Indivior in a research note on Friday, October 25th. Craig Hallum dropped their price objective on Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, October 11th.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.